May 22 (Reuters) – Amgen Inc’s closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.
Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that have the potential to drastically reduce the risk of heart attacks when used in addition to standard treatment.
France’s Sanofi and its partner, Regeneron Pharmaceuticals Inc, are developing a rival drug called Praluent, and both treatments have been running neck-and-neck in the sprint to market.
Neither has won approval in the all-important U.S. market yet.
The European Medicines Agency, on Friday, recommended approval for Repatha to be used in adult patients with hypercholesterolaemia or mixed dyslipidaemia and adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia. (http://bit.ly/1FrWu5K)
Recommendations for marketing approval by its Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
Numerous trials have shown that PCSK9 inhibitors significantly lower blood levels of “bad” LDL cholesterol, but widespread use will hinge on whether the drugs are proven to prevent heart attacks, other serious heart problems.
The experimental drugs are antibodies designed to target the PCSK9 protein that maintains LDL cholesterol in the bloodstream. They work differently from statins, which block the liver’s production of LDL cholesterol in the first place.
Both Amgen and Sanofi have filed for approval of their drugs based on trials showing that they lower LDL in patients whose cholesterol is not controlled by other drugs, those who cannot tolerate other drugs and people genetically predisposed to high cholesterol.